Baker BROS. Advisors LP Buys 464,936 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Baker BROS. Advisors LP increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 55.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,308,011 shares of the company's stock after acquiring an additional 464,936 shares during the period. CRISPR Therapeutics comprises approximately 0.5% of Baker BROS. Advisors LP's holdings, making the stock its 23rd largest holding. Baker BROS. Advisors LP owned approximately 1.53% of CRISPR Therapeutics worth $51,483,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics during the third quarter worth $40,000. Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth about $39,000. Western Pacific Wealth Management LP grew its holdings in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after acquiring an additional 500 shares during the last quarter. Spire Wealth Management increased its position in CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after acquiring an additional 1,482 shares in the last quarter. Finally, MCF Advisors LLC bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $80,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CRSP. Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a report on Wednesday. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a research note on Friday, March 21st. Morgan Stanley upped their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a research note on Friday, February 14th. Bank of America lowered their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Finally, Truist Financial upped their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of "Hold" and an average price target of $72.84.

Insider Buying and Selling

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at $350,516.46. This represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock worth $1,608,243 over the last ninety days. Company insiders own 4.10% of the company's stock.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP traded up $1.11 on Wednesday, reaching $34.27. The company's stock had a trading volume of 3,105,015 shares, compared to its average volume of 1,665,374. The firm has a market cap of $2.96 billion, a PE ratio of -7.84 and a beta of 1.88. The business's 50-day moving average price is $38.62 and its two-hundred day moving average price is $43.00. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the prior year, the firm earned ($1.43) EPS. The company's quarterly revenue was up 71.6% on a year-over-year basis. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.